^
    Back
    Association details:
    Biomarker:PAX5 overexpression
    Cancer:Diffuse Large B Cell Lymphoma
    Drug:Brukinsa (zanubrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    EHA 2020
    Title:

    BIOMARKER IDENTIFICATION IN RELAPSED/REFRACTORY NON-GERMINAL CENTER B-CELL–LIKE DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH ZANUBRUTINIB

    Published date:
    06/12/2020
    Excerpt:
    The retrospective biomarker analysis identified subsets of patients (such as PAX5 high or with CD79B mutations) with higher response rates to zanubrutinib treatment.